Loading organizations...
Loading organizations...
Science 37 operates as an FDA-inspected direct-to-patient clinical trial site, developing high-quality, innovative solutions that enable widespread participation in medical research. The company utilizes a decentralized clinical trial operating system, integrated with telemedicine technology and mobile nursing, to facilitate patient discovery, qualification, and engagement in studies regardless of their location. This approach aims to streamline the clinical research process by bringing trials to patients.
The company was co-founded by Noah Craft and Belinda Tan, who established Science 37 with the insight that technology could significantly broaden access to clinical trials. Their vision involved transforming traditional research models by allowing patients to participate remotely, thereby overcoming geographical and logistical barriers that often hinder study enrollment and diversity. Their early leadership positioned the firm as a pioneer in virtual clinical trials.
Science 37 primarily serves clinical trial sponsors seeking to expand patient access and accelerate drug development timelines. Its mission is to develop a world-class team of clinical researchers dedicated to delivering solutions that enable universal trial participation. The long-term vision is to foster a world where innovative therapies are approved more rapidly, leading to more equitable and improved health outcomes for all individuals.
Science 37 has raised $40.0M across 1 funding round.
Science 37 has raised $40.0M in total across 1 funding round.
Science 37 is a technology-driven clinical research company that builds a proprietary unified platform called the Metasite, enabling decentralized clinical trials (DCTs) where patients participate from home via telemedicine, eConsent, ePRO, wearable integration, and direct EHR access.[1][2][4] It serves pharmaceutical sponsors, biotech firms, and patients by solving key problems in traditional site-based trials, such as geographic barriers, slow enrollment, low diversity, and poor retention—achieving up to 21x faster enrollment, 28% better retention, and 3x more diverse populations.[3][5] The platform orchestrates end-to-end workflows for study staff and patients, including in-home nursing, logistics for investigational products, and real-time data capture, powering direct-to-patient sites with nationwide reach and FDA-inspected operations.[1][5][7] Recent growth includes 2023 MedTech Breakthrough and 2025 Clinical Trials Arena awards for platform innovation and site excellence, plus partnerships like Catalent for streamlined trial delivery.[1][5][6]
Founded over a decade ago by investigators frustrated with traditional trial limitations, Science 37 emerged from a vision to make clinical research accessible "anyone, anywhere, anytime," regardless of proximity to brick-and-mortar sites.[5] The idea took shape as pioneers in DCTs, developing a full-stack operating system (Science 37 OS) with networks of telemedicine investigators, mobile nurses, and patient communities to bypass geographic restrictions.[3][4] Early traction came from proving faster enrollment and higher retention in interventional trials, evolving into a Nasdaq-listed entity (SNCE) that leads in decentralized studies, with pivotal expansions like EHR integration and patient relationship management tech in 2022.[2][3]
Science 37 stands out in clinical trials through these key strengths:
Science 37 rides the DCT wave, fueled by post-pandemic demand for remote, patient-centric trials amid rising drug development costs and diversity mandates from regulators like the FDA.[1][5] Timing aligns with digital health maturation—EHR interoperability, wearables, and telehealth adoption—enabling real-world data from diverse, real-life settings over controlled sites.[2][3] Market forces like sponsor pressure for faster approvals (via 21x enrollment speed) and partnerships (e.g., Catalent for end-to-end sites) amplify its edge, while it influences the ecosystem by setting standards for virtual sites, boosting inclusion, and accelerating therapies for broader populations.[6][7]
Science 37 is poised to dominate DCT expansion as AI-driven recruitment, advanced wearables, and global regulatory nods further hybridize trials, potentially scaling its platform to international markets and complex therapies like cell/gene.[1][3] Trends like real-time EHR and predictive analytics will sharpen its enrollment edge, evolving influence from U.S. pioneer to global enabler of inclusive research. This builds on its core promise: universal trial access, transforming patient lives through technology that truly works for everyone.[4][9]
Science 37 has raised $40.0M in total across 1 funding round.
Science 37's investors include Dimension Capital, Lux Capital, The Column Group.
Science 37 has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Venture Round in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $40.0M Venture Round | Dimension Capital, Lux Capital, The Column Group |
